HCC lesions 5 cm in diameter.3 Based on the above data, we feel it is reasonable to utilize HCC lesions 4 cm as the key inclusion criteria for our study for both RFA and cryoablation (CRYO).For patients with tumor diameters of 3.1 to 4.0 cm, the 1-, 3-, and 5-year tumor-free survival (TFS) rates were 86%, 51%, and 29% in the CRYO group and 84%, 49%, and 30% in the RFA group, respectively. There was no significant difference between these two groups (P 5 0.88). Consistent with other studies, 2 we did not find that tumor size would significantly affect overall survival (OS) and TFS. But there was a significantly lower local tumor progression (LTP) rate in the CRYO group, compared to that in the RFA group (7 of 91 [7.7%] HCC lesions for cryoablation versus 14 of 77 [18.2%] for RFA, P 5 0.041).Regarding the effect of the alternative treatment for those with distant tumor recurrence (110 patients) on OS, Prof. Hyun is correct, in that combination therapy using transarterial chemoembolization (TACE), sorafenib, and local ablation could benefit the OS. Considering OS was influenced by many factors, we chose OS and TFS as the secondary endpoints. We did not collect more detailed information, such as the frequency of TACE or local ablation times, duration of sorafenib treatment, and time for conservative management. So, we did not analyze the effect of retreatments of HCC recurrence and metastasis on OS.It should be noted that at the time this study was designed, the greatest concern was the procedure-related complications. Thus, it is important to systemically assess the safety of cryoablation through a randomized, controlled trial (RCT) with comparison to RFA. It is also important to evaluate the efficacy of cryoablation for HCC by a RCT, and the LTP has been a standard measure of the primary endpoints. Our study has demonstrated that percutaneous cryoablation is safe and effective and should be one of the standard ablation modalities for HCC.